文献速递类风湿关节炎

类风湿关节炎临床试验结局评估的演变:范围综述

Evolution of outcome assessment in clinical trials of rheumatoid arthritis: A scoping review.
PubMed 文献 · Semin Arthritis Rheum · 2026-10-09

该范围综述纳入611项随机对照试验,梳理20世纪至21世纪类风湿关节炎临床试验结局报告的演变。疾病活动度指标从单项临床指标发展为ACR反应标准、DAS、DAS28、SDAI、CDAI等标准化复合指数,并逐步扩展至结构损伤、患者报告结局、影像学及生物标志物等多维评估。

要点

  • 疾病活动度是各年代最持续报告的结局,逐步转向标准化复合指数。
  • 结局评估逐步纳入结构损伤、患者报告结局、生活质量、影像与生物标志物。
  • 近期试验更强调缓解、达标治疗、先进影像及经验证的患者报告结局工具。

核心结论

  • 类风湿关节炎临床试验结局评估从症状导向转向涵盖临床、结构、功能、生物学和患者中心的多维评估。

研究设计与样本

  • 遵循Joanna Briggs Institute方法学并按照PRISMA-ScR报告的范围综述,检索PubMed/MEDLINE、Embase、PEDro和Google Scholar(1989年1月至2026年5月),纳入成人类风湿关节炎随机对照试验,由5名独立评价员进行文献筛选和数据提取。

主要发现

  • 检索共识别5209条记录,其中611项随机对照试验符合纳入标准。
  • 疾病活动度结局在所有年代中最持续被报告,并从单项临床指标演变为ACR反应标准、DAS、DAS28、SDAI和CDAI等标准化复合指数。
  • 结局评估逐步扩展至结构损伤、患者报告结局、躯体功能、健康相关生活质量、影像学、实验室生物标志物、安全性和卫生经济学指标。
  • 近期试验日益强调缓解、达标治疗策略、先进影像技术、经验证的患者报告结局测量工具和基于生物标志物的评估。

关键数值与推荐

  • 疾病活动度复合指数包括ACR反应标准、DAS、DAS28、SDAI和CDAI。

临床怎么用

  • 提示临床研究应采纳涵盖疾病活动度、结构损伤、患者报告结局、功能、生活质量和生物标志物的多维核心结局集。
  • 支持在临床实践中关注缓解和达标治疗策略,并结合经验证的患者报告结局工具进行评估。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To identify, map, and synthesize the outcomes reported in patients with rheumatoid arthritis and describe how these outcomes have changed over time throughout the 20th and 21st centuries. METHODS: A scoping review was conducted according to the Joanna Briggs Institute methodology and reported following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses Extension for Scoping Reviews (PRISMA-ScR). Electronic searches were performed in PubMed/MEDLINE, Embase, PEDro, and Google Scholar from January 1989 to May 2026. Randomized clinical trials involving adults with rheumatoid arthritis were eligible. Five independent reviewers performed study selection and data extraction. Reported outcomes were classified into conceptual domains and analyzed chronologically to identify temporal trends in outcome assessment. RESULTS: The search identified 5209 records, of which 611 randomized clinical trials met the eligibility criteria. Disease activity outcomes remained the most consistently reported across all decades, evolving from individual clinical measures toward standardized composite indices, including ACR response criteria, DAS, DAS28, SDAI, and CDAI. Outcome assessment progressively expanded to incorporate structural damage, patient-reported outcomes, physical function, health-related quality of life, imaging, laboratory biomarkers, safety, and health-economic measures. Recent trials increasingly emphasized remission, treat-to-target strategies, advanced imaging techniques, validated patient-reported outcome measures, and biomarker-based assessments, reflecting a more comprehensive and patient-centered approach to rheumatoid arthritis management. CONCLUSION: Outcome assessment in rheumatoid arthritis clinical trials has evolved substantially over the past four decades, transitioning from symptom-focused evaluation to multidimensional assessment encompassing clinical, structural, functional, biological, and patient-centered domains. This review synthesizes evidence from 611 randomized clinical trials and provides a comprehensive mapping of the historical evolution of outcome measurement, offering a valuable reference for future clinical research and the development of standardized core outcome sets.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Maciel-de-Sousa JMV, Lima RF, Duarte-Serejo MM, et al. Evolution of outcome assessment in clinical trials of rheumatoid arthritis: A scoping review. Semin Arthritis Rheum. 2026. PMID: 42863443. doi:10.1016/j.semarthrit.2026.153088

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。